Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now official registry

Prurigo Nodularis clinical trials

5 of 15 indexed Prurigo Nodularis trials are currently recruiting.

15 US clinical trials · 5 currently recruiting

Prurigo Nodularis is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Incyte Corporation, running 5 of these trials.

The research picture

Prurigo Nodularis has 15 registered US clinical trials, 5 of them open to new participants right now, about 33% of the total.

5
recruiting participants now
33%
of trials open to enrollment
8
in Phase 3–4 (later-stage)
5
top sponsor: Incyte Corporation
Phase 11Phase 24Phase 37Phase 41

Active & Recent Trials

15 total, page 1 of 1

RECRUITING 600 participants

Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults

Galderma R&D

NCT06988618

RECRUITING Phase 3 330 participants

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

Incyte Corporation

NCT06516965

RECRUITING Phase 3 330 participants

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

Incyte Corporation

NCT06516952

RECRUITING Phase 4 25 participants

Upadacitinib for Prurigo Nodularis

Psoriasis Treatment Center of Central New Jersey

NCT06773403

RECRUITING Phase 3 18 participants

A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

Sanofi

NCT06293053

ACTIVE NOT RECRUITING Phase 3 500 participants

A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Galderma R&D

NCT04204616

ACTIVE NOT RECRUITING Phase 3 469 participants

A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis

Amgen

NCT06527404

ACTIVE NOT RECRUITING Phase 2 140 participants

A Study of Barzolvolimab in Patients With Prurigo Nodularis

Celldex Therapeutics

NCT06366750

ACTIVE NOT RECRUITING 100 participants

Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study

Sanofi

NCT05991323

COMPLETED Phase 3 274 participants

A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Galderma R&D

NCT04501679

COMPLETED Phase 3 190 participants

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

Incyte Corporation

NCT05764161

COMPLETED Phase 2 146 participants

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis

Incyte Corporation

NCT05061693

COMPLETED Phase 2 62 participants

Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

Trevi Therapeutics

NCT02174419

COMPLETED Phase 1 23 participants

A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream

Incyte Corporation

NCT06213831

COMPLETED Phase 2 5 participants

Safety and Efficacy of CC-10004 for Prurigo Nodularis

University Hospitals Cleveland Medical Center

NCT00869089

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 4
Phase 3 7
Phase 4 1

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Prurigo Nodularis Trial Landscape

15 indexed Prurigo Nodularis studies · 5 recruiting (33%).

Phase mix: 8 late (III/IV) vs 5 early (I/II).

Top sponsor: Incyte Corporation (5 trials), 7 others listed. 15 shown below, recruiting first.

How to read this condition's trial landscape

That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Prurigo Nodularis?

PlainTrial tracks 15 US clinical trials for Prurigo Nodularis, of which 5 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Prurigo Nodularis?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.